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Sirtuins (SIRTs) are critical enzymes that govern
genome regulation, metabolism, and aging. Despite
conserved deacetylase domains, mitochondrial
SIRT4 and SIRT5 have little to no deacetylase activ-
ity, and a robust catalytic activity for SIRT4 has
been elusive. Here, we establish SIRT4 as a cellular
lipoamidase that regulates the pyruvate dehydroge-
nase complex (PDH). Importantly, SIRT4 catalytic
efficiency for lipoyl- and biotinyl-lysine modifications
is superior to its deacetylation activity. PDH, which
converts pyruvate to acetyl-CoA, has been known
to be primarily regulated by phosphorylation of its
E1 component. We determine that SIRT4 enzymati-
cally hydrolyzes the lipoamide cofactors from the
E2 component dihydrolipoyllysine acetyltransferase
(DLAT), diminishing PDH activity. We demonstrate
SIRT4-mediated regulation of DLAT lipoyl levels
and PDH activity in cells and in vivo, in mouse liver.
Furthermore, metabolic flux switching via glutamine
stimulation induces SIRT4 lipoamidase activity to
inhibit PDH, highlighting SIRT4 as a guardian of
cellular metabolism.
INTRODUCTION
Sirtuins (SIRTs) are a family of seven mammalian nicotinamide
adenine dinucleotide (NAD+)-dependent enzymes that regulate
diverse biological processes, including genome regulation,
stress response, metabolic homeostasis, and aging (Guarente,
2000; Imai et al., 2000). SIRTs display widespread subcellular
distributions, as SIRT1, SIRT6, and SIRT7 are nuclear, SIRT2 is
predominantly cytoplasmic, and SIRTs3–5 are mitochondrial
(Haigis et al., 2006; Michishita et al., 2005). As all SIRTs have a
conserved deacetylase domain, these enzymes are generally
known as lysine deacetylases, acting in opposition to acetyl-
transferases to remove acetyl-modifications from lysine residues
(Imai et al., 2000). However, SIRTs exhibit varying catalytic effi-
ciencies to this modification. SIRTs1–3 display robust deacety-
lase activity, in contrast to SIRTs4–5 that show little to no activity
(Haigis et al., 2006; Michishita et al., 2005; Schuetz et al., 2007).
Emerging evidence has revealed that several SIRTs can hydro-Clyze alternative lysine modifications more efficiently than acetyl.
Specifically, SIRT5 preferentially desuccinylates and demalony-
lates protein substrates (Du et al., 2011; Peng et al., 2011), while
SIRT6 can hydrolyze long-chain fatty acyl lysine modifications
(Jiang et al., 2013). These studies have highlighted the function-
ally dynamic nature of this family of proteins, which are able to
perform different enzymatic reactions and regulate a wide range
of cellular processes.
Mitochondrial SIRTs3–5 regulate ATP production, apoptosis,
and cell signaling (Verdin et al., 2010) through distinct enzy-
matic functions. SIRT3 is considered to be the major de-
acetylase of the mitochondria, as SIRT3-deficient mice exhibit
significant protein hyperacetylation (Lombard et al., 2007). The
desuccinylase activity of SIRT5 was shown to target proteins
involved in fatty acid b-oxidation and ketone body synthesis
pathways, with SIRT5-deficient mice exhibiting an accumula-
tion of acylcarnitines and a decrease in b-hydroxybutyrate
production (Rardin et al., 2013). More recently, SIRT5 was
reported to regulate lysine glutarylation levels, thereby modu-
lating the activity of carbamoyl phosphase synthase 1, a crit-
ical enzyme in the urea cycle (Tan et al., 2014). In contrast to
SIRT3 and SIRT5, SIRT4 enzymatic functions have generally
remained more elusive (Newman et al., 2012). SIRT4 has
been reported to regulate glutamine metabolism (Csibi et al.,
2013; Jeong et al., 2013) and fatty acid oxidation via PPAR-a
activity (Laurent et al., 2013a). To date, the enzymatic activity
of SIRT4 is largely based on its ability to ADP-ribosylate gluta-
mate dehydrogenase (GLUD1), which regulates amino-acid-
dependent insulin secretion (Haigis et al., 2006). The deacylase
activities of SIRT4 have remained less well characterized.
Initial studies reported limited deacetylation activity (Lin
et al., 2012; Michishita et al., 2005), yet SIRT4 was recently
reported to control lipid catabolism through deacetylation of
malonyl-CoA decarboxylase (MCD) (Laurent et al., 2013b).
Additionally, acetylated SIRT4 substrate candidates have
been identified in vitro via peptide microarrays (Rauh et al.,
2013) and by screening the activity of recombinant SIRTs
against various acyl-histone peptides (Feldman et al., 2013).
Unfortunately, these efforts may have been hampered by diffi-
culty in maintaining soluble and active recombinant SIRT4.
Therefore, reconciliation of in vitro enzymatic activities with
in vivo biological substrates and downstream physiological
functions remains a challenge.
Here, we characterized SIRT4 protein interactions within
mitochondria, identifying its association with proteins containingell 159, 1615–1625, December 18, 2014 ª2014 Elsevier Inc. 1615
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Figure 1. SIRT4 Interacts with the Pyruvate Dehydrogenase Complex
(A) Density gradient-based cellular fractionation of MRC5 cells isolates SIRT4-EGFP with mitochondrial marker COX IV.
(B) Functional network of SIRT4 interactions reveals association with dehydrogenase complexes. The E2 components in each complex (diamonds) contain
lipoamide modifications (red circle).
(C) SIRT4-EGFP (green) colocalizes with DLAT and PDHX (white) within mitochondria (MitoTracker Red).
(D) Immunoaffinity purification of SIRT4-EGFP coisolates DLAT and PDHX.
(E) Reciprocal immunoaffinity purification of DLAT coisolates endogenous SIRT4 in wild-type fibroblasts. See also Figure S1.lipoyl and biotinyl modifications. In agreement with this, we
demonstrate that SIRT4 removes lipoyl- and biotinyl-lysine
modifications more efficiently than acetylations. We discover
a physical and functional interaction between SIRT4 and the
components of the pyruvate dehydrogenase complex (PDH).
PDH is a mitochondrial complex comprised of three catalytic
subunits (E1, pyruvate decarboxylase; E2, dihydrolipoyllysine
acetyltransferase [DLAT]; E3, dihydrolipoyl dehydrogenase), a
structural subunit (PDH-binding component X [PDHX]) and
two regulatory subunits (PDH kinase and PDH phosphatase)
(Zhou et al., 2001). The complex catalyzes the decarboxylation
of pyruvate to generate acetyl CoA, and links glycolysis to the
TCA cycle. Its activity is known to be regulated by phosphory-
lation of the E1 subunit, phosphorylation that can be also
impacted by E1 acetylation (Fan et al., 2014; Jing et al.,
2013; Linn et al., 1969; Wieland and Jagow-Westermann,
1969). Here, we show that SIRT4 provides a previously unrec-
ognized, phosphorylation-independent, mechanism of PDH
regulation. SIRT4 hydrolyzes lipoamide cofactors from the
DLAT E2 component of the PDH complex, thereby inhibiting
PDH activity. Finally, as glutamine stimulation in rat liver is
also known to inhibit the PDH (Ha¨ussinger et al., 1982), we
investigated whether SIRT4 may play a role in this process.
Indeed, we show that glutamine stimulation induces endoge-
nous SIRT4 lipoamidase activity, triggering a reduction in
both DLAT lipoyl levels and PDH activity. As the PDH controls
pyruvate decarboxylation, fueling multiple downstream path-
ways, our findings highlight SIRT4 as a critical regulator of
cellular metabolism.1616 Cell 159, 1615–1625, December 18, 2014 ª2014 Elsevier Inc.RESULTS
SIRT4 Interacts with the Three Mitochondrial
Dehydrogenase Complexes
To investigate potential cellular substrates of SIRT4, we used
proteomics to define its mitochondrial protein interactions. We
constructed MRC5 fibroblasts stably expressing SIRT4-EGFP.
Using density-based organelle fractionation (coisolation with
mitochondrial COX IV, Figure 1A) and direct fluorescence mi-
croscopy (colocalization with MitoTracker, Figure 1C and Fig-
ure S1A available online), we confirmed its mitochondrial local-
ization. Mitochondria were isolated and the interactions of
SIRT4-EGFP were characterized by immunoaffinity purifica-
tion-mass spectrometry (IP-MS) (Joshi et al., 2013). Interaction
specificity was computationally assessed using SAINT (Choi
et al., 2011), and 106 significant SIRT4 candidate interactions
were identified (Table S1), including the known interactions
and substrates, GLUD1, IDE and MLYCD (Ahuja et al., 2007;
Haigis et al., 2006; Laurent et al., 2013b). We hypothesized
that as yet unrecognized substrates were also identified,
and interrogated SIRT4 interactions using bioinformatics to
extract enriched metabolic pathways and assemble functional
protein networks. Notably, pyruvate metabolism, the TCA
cycle, branched-chain amino acid catabolism, and biotin
metabolism were significantly enriched pathways (Figure S1).
Interaction of SIRT4 with biotin-dependent carboxylases has
been reported (Wirth et al., 2013), validating the reliability of
our data set. Interestingly, we found that SIRT4 associated
with all three of the multimeric mammalian dehydrogenase
Table 1. Determination of In Vitro SIRT4 Kinetics with Acyl-Modified Peptide Substrates
Peptide substrate Sequence kcat (s
-1) Km (mM) kcat/Km (s
-1M-1)
H3 K9 Acetyl KQTARKSTGGWW ND* ND* (>2500) 0.083 ± 0.004
H3 K9 Biotinyl 0.0005 ± 0.0001 719 ± 79 0.74 ± 0.05
H3 K9 Lipoyl 0.0019 ± 0.0002 814 ± 163 2.30 ± 0.30
DLAT K259 Acetyl EIETDKATIGW ND* ND* (>2500) 0.20 ± 0.01
DLAT K259 Lipoyl 0.0018 ± 0.0001 239 ± 51 7.65 ± 1.31
MCD K471 Acetyl SYLGSKNIKASEW ND* ND* (>2500) 0.0064 ± 0.0006
Synthetic peptide sequences are shown containing themodified lysine residues (underlined) as indicated by peptide substrate.When appropriate, kcat,
Km, and kcat/Kmwere determined by modeling of kinetic data using the Briggs-Haldane approach (see Figures 2D-E andMaterials andMethods). *ND,
kcat and Km could not be determined because v0 versus [S] was linear. For these cases, kcat/Kmwas calculated by linear regression of v0/[SIRT4] versus
[S]. SIRT4 enzyme concentration = 5 mM.complexes—PDH, oxoglutarate dehydrogenase (OGDH), and
branched-chain alpha-keto acid dehydrogenase (BCKDH) (Fig-
ure 1B). These complexes occupy discrete positions within the
cellular metabolic landscape, regulating TCA cycle activity and
amino acid metabolism (Figure S1C). Given its relative promi-
nence within SIRT4 interactions, we focused on PDH. The
PDH complex is known to be regulated by reversible phosphor-
ylation of its E1 component (Linn et al., 1969; Wieland and Ja-
gow-Westermann, 1969), with acetylation of E1 also impacting
its phosphorylation levels (Fan et al., 2014; Jing et al., 2013). We
confirmed that SIRT4-EGFP colocalized (Figure 1C) and immu-
noisolated (Figure 1D) with DLAT and PDH component X
(PDHX), the E2 and E3 subunits of PDH, respectively (Figure 1B).
Furthermore, in wild-type (WT) human fibroblast cells, we
confirmed that DLAT interacts with endogenous SIRT4 by recip-
rocal IP (Figure 1E).
SIRT4More Efficiently Catalyzes Removal of Lipoyl- and
Biotinyl- Than Acetyl-Lysine Modifications
Given our confirmation of SIRT4 interaction with the PDH com-
ponents, we pursued their functional relationship. The lipoa-
mide cofactors bound to E2 transferase enzymes (Figure 1B,
‘‘L’’) are required for PDH activity (Rahmatullah et al., 1990),
forming the intermediate S-acetyldihydrolipoyl-lysine in the
production of acetyl-CoA. DLAT also has a structural role,
constituting the PDH catalytic core. As other mitochondrial
SIRTs can hydrolyze various lysine modifications (Du et al.,
2011; Jiang et al., 2013), and as DLAT was prominent in our
SIRT4 isolation, we speculated that E2 dehydrogenase compo-
nents may be biological substrates of SIRT4 and that SIRT4
may directly hydrolyze the lipoamide cofactor. To test this,
we screened the in vitro activity of recombinant SIRT4 against
differentially-modified synthetic peptides (Table 1). Initially,
SIRT4 was incubated with histone H3 Lys9 (H3K9) peptides
modified with acetyl-, biotinyl-, or lipoyl-lysine, in the presence
or absence of NAD+. Following the reaction, the generated un-
modified peptides and remaining unreacted substrates were
quantified by LC-MS (Figures 2A–2D and Figure S2). SIRT4
only exhibited enzymatic activity in the presence of NAD+,
shown by the generation of a product peak (P) at 16.5 min
(Figure 2A), corresponding to the unmodified H3K9 (Fig-
ure S2A). To compare the relative preference of SIRT4 for the
different acyl-lysine peptides, we used extracted ion chro-Cmatograms to quantify the percentage of unmodified peptide
generated for each substrate (Figure 2B). SIRT4 showed the
highest potency for removing the lipoyl modification (Figure 2B).
The relative amount of unmodified product generated after
reaction with SIRT4 was 11% (lipoyl), 3% (biotinyl), and 0.3%
(acetyl) (Figure 2B, H3K9 substrates). To show that the enzy-
matic activity of SIRT4 was required for hydrolysis, we purified
a recombinant SIRT4 containing a mutation to the critical
residue H161. This histidine, conserved among all SIRTs, is
critical for NAD+ and substrate binding (Frye, 1999; Smith
and Denu, 2006). In contrast to wild-type SIRT4, deacylation
assays using the catalytically inactive SIRT4 H161Y resulted
in no significant activity against any of these acyl-modified
substrates (Figure 2C).
SIRT4 Has Superior Lipoamidase Activity for
Lipoyl-Modified PDH Peptides
To characterize the putative biological substrates of SIRT4, we
tested whether SIRT4 removed lipoamide from DLAT and
PDHX peptides (Figures 2B, 2D, S2B, and S2C). SIRT4 showed
greater activity toward these substrates than for H3K9, as the
proportion of unmodified peptide generated in the presence of
NAD+ increased to 33% for DLAT and 42% for PDHX (Figure 2B,
Lipoyl PDH substrates, and Figure 2D).
Having established SIRT4 enzymatic activity, we next per-
formed steady-state enzyme kinetic assays. This allowed direct
comparison of SIRT4’s catalytic efficiency for the various acyl-
modified peptide substrates (Table 1). Compared to H3K9
acetyl, SIRT4 removed lipoyl and biotinyl H3K9 modifications
28-fold and 9-fold more efficiently, respectively (Figure 3A,
Table 1). The DLAT lipoyl peptide displayed a 3.3-fold increase
in efficiency compared to H3K9 lipoyl, owing mainly to a
decreased Km (Figures 3A and 3B, Table 1). As a deacetylase,
SIRT4 showed slightly greater efficiency toward DLAT acetyl
compared to H3K9 acetyl; however, this efficiency was still 38-
fold lower than DLAT lipoyl (Figures 3B and S3A). We also
compared SIRT4’s ability to deacetylate the known biological
substrate peptide from MCD (Laurent et al., 2013b) and found
that SIRT4 was 1,270-fold more efficient at hydrolyzing
DLAT lipoyl (Table 1, Figure S3A). Altogether, our results demon-
strate that SIRT4 has a higher NAD+-dependent lipoamidase
than deacetylase activity, directly hydrolyzing lipoyl-lysine to
generate unmodified lysine (Figure 2E).ell 159, 1615–1625, December 18, 2014 ª2014 Elsevier Inc. 1617
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Figure 2. SIRT4 Hydrolyzes Lipoyl-, Biotin-,
and Acetyl-Lysine Modifications In Vitro
(A) Recombinant SIRT4 (5 mM) was incubated with
various acyl-modified H3K9 peptides (10 mM) with
or without NAD (1 mM), and product and residual
substrate peptides detected by LC-MS after
reaction. Representative extracted ion chromato-
grams show unreacted acyl-modified H3K9 sub-
strates (S), and unmodified H3K9 products (P,
16.5 min). +NAD chromatograms are offset for
clarity.
(B) The percentage of product (unmodified pep-
tide) formed as a function of increasing concen-
tration of wild-type SIRT4 (±NAD) (mean ± SEM;
n = 3).
(C) Same as (B), except product formation from
H3K9 substrates after reaction with increasing
concentration of catalytically inactive SIRT4
H161Y.
(D) Same as (A), except SIRT4 was incubated with
putative biological DLAT and PDHX lipoyl lysine
peptides (10 mM). Representative extracted ion
chromatograms of unreacted DLAT and PDHX
lipoyl peptide substrates (S) and unmodified
products (P).
(E) Scheme depicting the NAD+-dependent deli-
poylation of lipoyl-lysine mediated by SIRT4 lip-
oamidase activity. See also Figure S2.SIRT4 Is the Most Efficient Lipoamidase In Vitro among
Mitochondrial Sirtuins
To evaluate the lipoamidase activity for the three known mito-
chondrial sirtuins (SIRT3–5), we used steady-state enzyme ki-
netics to compare their ability to hydrolyze lipoyl or acetyl
lysine modifications (Figures 3C and 3D). For SIRT5, low but
detectable activity was measured for DLAT acetyl (Figure S3B),
while no activity was detected for DLAT lipoyl reactions (Fig-
ure S3C). As predicted, SIRT3, a robust mitochondrial deacety-
lase, showed significant enzymatic activity toward DLAT acetyl,
while SIRT4 had minimal activity (800-fold lower) (Figures 3C
and S3C). In contrast, although SIRT3 displayed some enzy-
matic activity toward DLAT lipoyl (Figure 3D), its efficiency
was 13-fold lower when compared to DLAT acetyl (Figure 3D
versus 3C). Thus, SIRT4 has the highest catalytic efficiency
for lipoamide modifications compared to the other mitochon-
drial SIRTs.
SIRT4 Lipoamidase Activity Diminishes Cellular PDH
Lipoamide Levels and Inhibits Its Activity
Given that the lipoamide cofactor is essential for PDH function
(Perham, 1991), we examined the impact of elevated SIRT levels
on the endogenous cellular activity of PDH by overexpression
(OE) of each mitochondrial SIRT in cultured human fibroblasts.1618 Cell 159, 1615–1625, December 18, 2014 ª2014 Elsevier Inc.Strikingly, PDH activity was only dimin-
ished in fibroblasts stably expressing
SIRT4 compared to cells overexpressing
GFP (CTL), SIRT3, or SIRT5 (Figures 4A,
S4A, and S4B). While SIRT3 displayed
marginal in vitro enzymatic activity for
the DLAT lipoyl peptide (Figure 3D), OEof either SIRT3 or SIRT5 did not alter cellular PDH activity (Fig-
ures 4A and S4B), reinforcing the cellular specificity of SIRT4.
We further confirmed the direct involvement of SIRT4 activity
by showing that PDH activity was not reduced by OE of
SIRT4 H161Y (Figures 4A and S4A). Concomitant with the
SIRT4-mediated reduction in PDH activity, we observed
reduced lipoylation of endogenous DLAT in SIRT4 OE cells,
while total DLAT levels remained constant (Figure 4B). DLAT
lipoyl levels were not altered in SIRT3 or SIRT5 OE cells. To
further characterize the correlation between SIRT4 OE and the
decrease in PDH activity and lipoyl levels, we measured phos-
phorylation of PDH-E1a. Interestingly, we observed reduced
phosphorylation at all three sites of E1a in SIRT4 OE cells, while
total E1a levels remained constant (Figure 4C). Expression of
H161Y SIRT4 did not change phosphorylation levels at any of
the E1 sites (Figure 4C), indicating that SIRT4 enzymatic activity
is required.
To confirm that the inhibition of PDH activity in cells reflects
a direct effect of SIRT4 on the complex, we immunocaptured
and measured the activity of purified porcine PDH in vitro (Fig-
ures 4D and S4C). Purified PDH was treated with pyruvate de-
hydrogenase phosphatase catalytic subunit 1 (PDP1), which
decreased the phosphorylation of all three inhibitory PDH-E1a
sites and, as expected, increased PDH activity (Figures 4D
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Figure 3. Steady-State Kinetics Reveals
SIRT4 Has the Highest Catalytic Efficiency
for Lipoyl-Modified Substrates amongMito-
chondrial SIRTs
(A and B) SIRT4 (5 mM) initial velocity (v0) versus
substrate concentration [S] for (A) H3K9- and (B)
DLAT-acyl peptides (mean ±SEM; n = 3). v0 versus
[S] were linear for acetyl substrates and were re-
plotted to estimate kcat/Km (see Figure S3A).
(C and D) Comparison of SIRT3 (0.5 mM) and
SIRT4 (0.5 mM) initial velocity versus [S] for DLAT
K259 (C) acetyl and (D) lipoyl peptide (mean ±
SEM; n = 3). SIRT4 v0 versus [S] was linear for
DLAT acetyl and was replotted to estimate kcat/
Km (see Figure S3B). If no error bars are dis-
played, errors were smaller than the data point
size. See also Figure S3.and S4C). Then, ‘‘activated’’ PDH was treated with either re-
combinant WT or inactive H161Y SIRT4. Only active SIRT4
was able to attenuate PDH activity, which was not due to
increased phosphorylation of E1 (Figure 4D). Overall, these
in vitro data with purified PDH support our observations of
reduced activity of PDH in SIRT4 OE cells (Figures 4A–4C),
and together suggest that reduction in PDH activity occurs in
a phosphorylation-independent manner, by SIRT4 directly hy-
drolyzing lipoylated DLAT.
DLAT contains two lipoyl-lysine residues, K132 and K259.
Since western blot analysis only assessed overall lipoyl protein
content, we designed an assay using LC-MS/MS selected reac-
tion monitoring (SRM) (Sherrod et al., 2012; Tsai et al., 2012) to
measure the effect of SIRT4 on specific lipoylated lysines of
endogenous cellular DLAT. Toward this goal, we affinity-purified
endogenous DLAT from fibroblast mitochondria and then per-
formed protein digestion using the endoproteinase GluC. Using
nontargeted LC-MS/MS the two predicted lipoyl-lysine peptides
of endogenous DLAT, containing K132 and K259 residues, were
identified (Figures 4E and S4E). We confirmed these results us-
ing a synthetic K259 lipoyl peptide, which showed a similar LC
retention time and fragmentation pattern as the endogenous
K259 peptide (Figure S4F). Additionally, fragmentation of these
lipoyl-lysine peptides generated b-ions suitable for relative
quantification by targeted MS/MS (Figure 4E, boxes). Using
this SRM assay, wemeasured the effect of SIRT4 OE on the rela-
tive levels of endogenous DLAT K132 lipoyl and K259 lipoyl in
mitochondria (Figures 4F and S4G). Stable expression of active
SIRT4 in fibroblasts reduced levels of DLAT lipoyl at both lysine
residues (Figure 4F, left), consistent with our western blotting re-
sults (Figure 4B). In contrast, expression of SIRT4 H161Y did not
reduce DLAT lipoyl levels. We also analyzed relative lipoyl levels
on endogenous DLAT in HEK293 cells transiently transfected
with either mCherry (CTL), SIRT4, or SIRT4 H161Y. Only expres-
sion of active SIRT4 diminished levels of DLAT lipoyl (Figure 4F,Cell 159, 1615–1625, Deright), suggesting that SIRT4 reduction
of DLAT lipoyl levels were not unique to
fibroblasts or an artifact from cell line gen-
eration. Altogether, our results demon-
strate that the E2 component of the PDHis a biological substrate of SIRT4 lipoamidase activity, and that
the SIRT4-mediated reduction in PDH lipoyl levels leads to an
inhibition of its function.
Glutamine-Stimulation Induces Endogenous SIRT4
Lipoamidase Activity and Inhibits PDH Activity
Glutamine stimulation in rat liver is known to cause increased flux
through OGDH and decreased flux through PDH, leading to PDH
inhibition (Ha¨ussinger et al., 1982). Therefore, we investigated
whether SIRT4 may play a role in this process. Stimulation of
WT fibroblasts with the glutamine supplement glutamax (4 mM)
caused a significant time-dependent decrease in PDH activity
(Figures 5A, S5A and S5B). Importantly, this reduction in activity
was not due to increased levels of inhibitory PDH-E1 phosphor-
ylation relative to unstimulated cells at the same time points (Fig-
ure 5B). While steady-state levels of DLAT were unchanged due
to glutamax stimulation (Figure 5B), a decrease in DLAT lipoyl
levels was observed within 72 hr (Figure 5C). In agreement with
these observations, we detected elevated expression of endog-
enous SIRT4 in cells stimulated with glutamax (Figure 5B). To
validate the dependence of PDH inhibition on SIRT4 activity,
we measured PDH activity in SIRT4 OE cells stimulated with glu-
tamax. Following 40 hr culture in glutamax, overexpression of
active WT SIRT4 triggered pronounced PDH inhibition, in
contrast to the H161Y catalytic mutant (Figure S5C). To test
the specific involvement of endogenous SIRT4, we generated
fibroblasts with knockdown SIRT4 expression using shRNA
(Table S2). Effective SIRT4 knockdown was confirmed at the
mRNA level (shSIRT4 #1 and #5 achieving > 75% knockdown)
(Figure 5D) and at the protein level (Figure 5E). Importantly,
SIRT4 knockdown using two different shRNA constructs led to
a partial rescue of the glutamax-mediated inhibition of PDH ac-
tivity (Figures 5F, S5D, and S5F). Finally, to confirm a role for
PDH regulation via SIRT4 in vivo, PDH activity was measured
in mitochondria purified from the liver of SIRT4 knockout (KO)cember 18, 2014 ª2014 Elsevier Inc. 1619
A D
B
C
E
F
Figure 4. Elevated SIRT4 Expression De-
creases the Activity and Lipoylation of the Py-
ruvate Dehydrogenase Complex in Cultured
Cells
(A) PDH activity in fibroblasts expressing mitochon-
drial SIRT proteins versus GFP-expressing cells
(CTL) (mean ± SEM; n = 3 SIRTs 3–5; n = 5 GFP;
****p < 0.0001) measured by a PDH immunocapture
colorimetric assay.
(B) Western blot analysis of endogenous, full-length
lipoylated DLAT in cells overexpressing mitochon-
drial SIRTs. DLAT and COX IV, loading controls.
(C) Western blot analysis of regulatory PDH-E1a
phosphorylation (pS232, pS293, pS300) upon over-
expression of SIRT4, catalytically inactive mutant
H161Y, or GFP (CTL). E1, loading control.
(D) Relative PDH activity of untreated (control) or
‘‘activated’’ (+pyruvate dehyrogenase phosphatase,
PDP1) purified porcine PDH complex incubated with
wild-type or H161Y SIRT4. Western blot analysis of
PDH-E1a phosphorylation sites; E1, loading control.
(E) Representative MS/MS spectra of K132 lipoyl
peptide detected from endogenous DLAT im-
munopurified from mitochondria of fibroblasts and
digestedwith endoproteinaseGluC. K*, reduced and
di-carbamidomethylated lipoyl-lysine (Dm = 304
amu versus unmodified lysine).
(F) SRM quantification of endogenous DLAT lipoyl
K132 and K259 in fibroblasts (left) and HEK293 cells
(right) (mean ± S.E.M; n = 3, *p = 0.03, ***p = 0.0003).
See also Figure S4.
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Figure 5. Endogenous SIRT4 Inhibits PDH in Cultured Fibroblasts
and In Vivo, in Mouse Liver
(A) PDH activity time course in wild-type fibroblasts stimulated with glutamax
(4 mM) for 2, 3, and 8 days, versus unstimulated cells (mean ± SEM; n = 4 2D
and 3D, p < 0.0001; n = 3 8D, p = 0.0007).
(B) Western blot analysis of regulatory PDH-E1a phosphorylation sites and
total E1 (loading control), and endogenous SIRT4, DLAT, and COX IV (loading
control) levels, following glutamax stimulation.
(C) SRMquantification of DLAT lipoyl levels (K132 and K259) in cells stimulated
with glutamax versus unstimulated (mean ± SEM; n = 3) for 2D (ns), 3D (*p =
0.015), and 8D (**p = 0.007, *p = 0.018).
(D) Relative SIRT4 mRNA expression measured by qRT-PCR in fibroblast
stably expressing either nontargeting control shRNA (shCTL) or one of five
different constructs targeting SIRT4 (shSIRT4 #1–5).
(E) Western blot analysis of SIRT4 and COX IV (loading control) from mito-
chondria purified from fibroblasts expressing shRNA constructs shCTL,
shSIRT4 #1, and shSIRT4 #5.
(F) PDH activity in fibroblasts with knockdown levels of endogenous SIRT4
(shSIRT4 #1 or #5, mean ± S.E.M; n = 4) treated with glutamax (4 mM for 8D),
versus control shCTL cells (mean ± S.E.M; n = 7, ***p < 0.0001).
Cmice. Indeed, we observed elevated PDH activity (Figures 5G
and S5E) and DLAT lipoyl levels (Figure 5G) in SIRT4 KO mice
relative to control mice. Altogether, these data demonstrate
that endogenous SIRT4 is involved in inhibiting PDH activity
and DLAT lipoyl levels in the mitochondria of cells and in vivo
in mouse liver.
DISCUSSION
Until now, a mammalian cellular lipoamidase has not been char-
acterized. However, our study discovered that SIRT4 can func-
tion with this enzymatic capacity in the mitochondria, and that
PDH is a biological substrate. We find that, compared to its cat-
alytic efficiency for deacetylation, SIRT4 exhibits far superior
enzymatic activity for lipoyl- and biotinyl-lysine modifications.
Interestingly, there is precedence for a serum lipoamidase hav-
ing enzymatic activity for both lipoyl- and biotinyl-lysine modifi-
cations (Nilsson and Ka˚gedal, 1993). Importantly, patients with
severe serum biotinidase deficiency were observed to exhibit
lipoamidase deficiency (Nilsson and Ronge, 1992). Given the
serum enzyme was unable to hydrolyze lipoamide from bovine
heart PDH (Oizumi and Hayakawa, 1989), it is tempting to spec-
ulate that SIRT4 is the mitochondria-specific member of the
mammalian class of enzymes that possess both lipoamidase
and biotinidase activity and therefore may be unique among
these enzymes to liberate lipoate from PDH.
SIRT4 is among the least abundant proteins in the human pro-
teome (PaxDb, www.paxdb.org), and there is only a limited num-
ber of human proteins known to be lipoylated. These proteins
play critical roles in cellular metabolism and include DLAT,
DLST, DBT, PDHX, andGCSH—the first four of which were iden-
tified as specific interacting partners of SIRT4 in our IP-MS
study. We determined in vitro, in cells, and in a mouse model
that SIRT4 regulates overall PDH activity by hydrolyzing the
lipoamide cofactors from DLAT. Importantly, we showed that
a catalytically active SIRT4 is required for this arm of PDH regu-
lation. Overall, PDH controls pyruvate decarboxylation to
generate acetyl-CoA, and DLAT specifically performs the trans-
acetylation reaction, transferring the acetyl-group to Coenzyme
A. Our finding that SIRT4 regulates DLAT lipoylation suggests
PDH is inhibited via diminished transacetylation. Interestingly,
the accessory PDH E3-binding subunit (PDHX) also contains a
lipoyl modification. Indeed, we detected lipoylated protein(s) at
50 KDa bywestern blotting (Figure S4D). This signal may repre-
sent individual DLST, DBT, PDHX, or a mixture of these proteins
(with similar masses at 49–54 kDa), or other potential SIRT4 sub-
strates. Although this band was reduced in cells upon SIRT4
overexpression (Figure S4D), there was no clear difference in
mouse liver from SIRT4 KO when compared to WT mice (Fig-
ure S5G). In contrast, DLAT lipoyl levels (70K band) were
reduced in cells overexpressing SIRT4 (Figure 4B) and enhanced
in SIRT4 KO versus wild-type mice (Figure S5G). This highlights
the significance of lipoylated DLAT under SIRT4 null conditions.(G) PDH activity, lipoyl levels of endogenous DLAT (lipoic acid), and total
DLAT levels (DLAT) from mouse liver mitochondria of Sirt4/ mice (mean ±
S.E.M, n = 3, **p < 0.039) versus wild-type control (n = 4). See also
Figure S5.
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Additionally, rather than performing a catalytic function, PDHX is
known to play a structural role, such as in anchoring the E3 to the
E2 (DLAT) subunit (Brautigam et al., 2006; Harris et al., 1997).
Thus, should SIRT4, in addition to its impact on DLAT, modulate
PDH activity through delipoylation of PDHX, it may involve a
structural impairment of PDH. In addition, given our identification
of SIRT4 interactions with biotin-dependent decarboxylases and
demonstration that SIRT4 also has activity for biotinyl lysine, we
predict that SIRT4 regulates decarboxylase activity and poten-
tially other biotin-dependent enzymes and metabolic pathways.
Comparison of steady-state enzyme kinetics is important for
determining the catalytic efficiency of an enzyme for particular
substrates. However, this has been notoriously difficult for
SIRT4 given issues associated with maintaining recombinant
protein solubility (Du et al., 2011). Enzyme kinetics have not
been reported for SIRT4 substrates prior to this study, and
although some in vitro activity of SIRT4 toward reduced lipoa-
mide H3K9 peptide has been reported recently (Feldman et al.,
2013), the activity was not reproducible, and at very low levels
(presumably due to stability issues). We optimized the expres-
sion, purification, and storage of SIRT4, which allowed us
to perform steady-state kinetics assays and show that SIRT4
has the predominant lipoamidase activity among the
mitochondrial sirtuins. Furthermore, SIRT4 catalytic efficiency
for lipoylated DLAT is far-superior (1,270-fold) to its previously
reported substrate, acetylated MCD, making DLAT the best
characterized substrate to date. Importantly, the observed
SIRT4 catalytic efficiency and binding constant, Km, for DLAT-
lipoyl is consistent with the cellular lipoyl status of PDH. Specif-
ically, each of the DLAT lipoyl domains is concentrated within
PDH at >1 mM (Roche et al., 1993), supporting a cellular role
for SIRT4 lipoamidase activity in regulating PDH activity. Indeed,
if SIRT4 is actually embedded within the PDH, this finding may
help explain the previously reported inability to detect SIRT4
within the mitochondrial matrix by either proteomic profiling
(Rhee et al., 2013) or immunofluorescence (www.proteinatlas.
org).
Compared to the other mitochondrial SIRTs, our study shows
that the cellular lipoamidase activity on DLAT-lipoyl and PDH
activity is unique to SIRT4. Elevated expression levels of SIRT3
and SIRT5 in cells did not affect DLAT-lipoyl levels or PDH activ-
ity, despite SIRT3 showing some in vitro enzymatic activity to-
ward DLAT-lipoyl in kinetic assays. This highlights that the com-
plex architecture and the local cellular environment facilitate
protein interactions that may help to define substrate specificity.
SIRT4 substrate specificity may also be determined by the size
of the active site and amino acids that line the catalytic pocket.
For example, structural analysis of the SIRT5 active site defined
its preference for lysine substrates bearing negatively charged
carboxylates (Du et al., 2011). However, in contrast to all previ-
ously characterized SIRT substrates, lipoamide has a sulfur-con-
taining, dithiolane ring. Assuming the SIRT4 active site is near
physiological pH, lipoamide will have a neutral charge and may
not require extensive charge stabilization. Overall, our results
show SIRT4 lipoamidase activity for nonreduced lipoamide
in vitro (Figure 2); however, the oxidative susceptibility of lipoa-
mide raises the possibility of other in vivo substrates. Ultimately,
given the current lack of a SIRT4 crystal structure, future studies1622 Cell 159, 1615–1625, December 18, 2014 ª2014 Elsevier Inc.will be required to delineate the full range of SIRT4 lipoamide
substrate specificity under different cellular states.
Our discovery that SIRT4 inhibits the PDH via direct hydroly-
sis of the lipoamide cofactor builds on the knowledge accumu-
lated during several decades to provide a new perspective for
understanding PDH regulation. PDH activity is understood to
be principally inhibited by kinase-dependent phosphorylation
of the E1 subunit, whereby phosphorylation is modulated down-
stream of E1 acetylation (Fan et al., 2014; Jing et al., 2013; Linn
et al., 1969; Wieland and Jagow-Westermann, 1969). Our
finding that SIRT4 lipoamidase activity can directly impair the
function of the complex underscores that PDH regulation is a
highly complex process that involves several mechanisms. For
instance, we observed that cells with elevated levels of SIRT4
actually have decreased E1 phosphorylation, in conjunction
with reduced PDH activity and lipoyl levels. Reduced phosphor-
ylation would normally be expected to activate PDH. Neverthe-
less, this result is not entirely unexpected and may be partly
explained if one considers that PDH kinases are activated
via binding to the lipoyl domain (Radke et al., 1993). Therefore,
if SIRT4 reduces DLAT lipoamide levels it also triggers an
indirect reduction in kinase binding sites, thereby limiting kinase
function and causing reduced phosphorylation. Thus, the
complex regulation of PDH likely involves the temporal activa-
tion of several mechanisms by different stimuli and cellular
responses.
Glutamine stimulation in rat liver was shown to inhibit PDH
activity by increasing flux through OGDH, accompanied by
decreased flux through PDH (Ha¨ussinger et al., 1982). Building
on this knowledge, we demonstrated that endogenous SIRT4
lipoamidase activity could be induced via glutamine stimulation.
Interestingly, after 48 hr of glutamine stimulation the PDH activ-
ity decreased by 50%, while the DLAT lipoyl levels decreased
to a lesser extent. At subsequent time points, substantial de-
creases in both PDH activity and DLAT lipoylation were
observed. These results suggest that PDH inhibitory mecha-
nisms are temporally regulated. For instance, it is possible
that a lipoyl-independent mechanism impacts PDH activity early
after glutamine stimulation (up to 48 hr), which is followed by a
lipoyl-dependent mechanism that relies on increased SIRT4
levels and lipoamidase activity (72 hr to 8 days). The underlying
molecular mechanisms for this temporal regulation are not
entirely understood, but may reflect time requirements for
increased transcription or translation of SIRT4. Nonetheless,
knockdown of SIRT4 in cells led to a partial rescue of the gluta-
mine-mediated inhibition of PDH activity. It remains to be deter-
mined whether the lack of a full rescue is due to the function of
residual SIRT4 in these knocked-down cells or if another, yet to
be identified, PDH inhibition mechanism is simultaneously
active. Finally, PDH activity and DLAT lipoyl levels in SIRT4
KO mouse liver were elevated compared to control animals,
further supporting the function of SIRT4 in regulating PDH activ-
ity in vivo.
SIRT4 was initially characterized as an ADP-ribosyltransferase
that regulates glutamate dehydrogenase and insulin secretion
(Haigis et al., 2006). Studies in insulin producing cells with knock-
down SIRT4 expression showed elevated insulin secretion
in response to glucose (Ahuja et al., 2007). Our discovery that
SIRT4 inhibits PDH activity has interesting implications for
further understanding this phenotype, as insulin secretion is initi-
ated by the rapid utilization of glucose for glycolysis and the
consequent entry into the TCA cycle for oxidative phosphoryla-
tion (Newgard and McGarry, 1995). Thus, SIRT4 knockdown
would help to accelerate this process. SIRT4 has also been re-
ported to regulate fatty acid oxidation via expression of catabolic
genes (Laurent et al., 2013a; Nasrin et al., 2010), and by deace-
tylation of MCD, which inhibits conversion of malonyl-CoA to
acetyl-CoA (Laurent et al., 2013b). Our finding that SIRT4 is a lip-
oamidase is consistent with a function in this metabolic process
and highlights PDH as another molecular target that also nega-
tively regulates acetyl-CoA production. SIRT4 has also been re-
ported to be involved in cancer progression. Lung tumors spon-
taneously develop in SIRT4 KO mice, while expression of SIRT4
represses tumor development in vivo (Csibi et al., 2013; Jeong
et al., 2013). Reduced levels of SIRT4 have also been detected
in human bladder, breast, colon, gastric, and ovarian carcinoma,
relative to normal tissues (Csibi et al., 2013). The aforementioned
observations suggest that SIRT4 acts a as a tumor suppressor
(Zhu et al., 2014), primarily by inhibiting carcinogenesis through
repression of glutamine anaplerosis (Jeong et al., 2013). Thus, it
is tempting to speculate that this regulation may also involve
SIRT4 lipoamidase activity toward OGDH, which contains
DLST-lipoyl and feeds 2-oxoglutarate into the TCA cycle.
Taken together, our results identify SIRT4 as a cellular lipoami-
dase, which regulates the activity of the PDH complex via
enzymatic hydrolysis of the lipoamide cofactor. As PDH controls
pyruvate decarboxylation, fueling multiple downstream path-
ways, our findings highlight SIRT4 as a critical regulator of
cellular metabolism. We anticipate that these findings will trigger
future studies aimed at further characterizing the roles of SIRT4’s
lipoamidase activity in mitochondrial function in diverse health
and disease states.
EXPERIMENTAL PROCEDURES
Cell Culture and Generation of Stable Cell Lines
Human MRC5 fibroblasts and embryonic kidney HEK293 cells were cultured
in DMEM containing 10% (v/v) Benchmark fetal bovine serum and 1% peni-
cillin-streptomycin solution. Stable cell lines that express SIRT4-EGFP,
SIRT4-EGFP H161Y, or GFP control, as well as stable cell lines with knock-
down expression of SIRT4 (using SIRT4-targeting shRNA) or control shRNA
were generated as described in Extended Experimental Procedures. SIRT4
expression levels were measured by western blotting, and knockdown effi-
ciency was measured by qRT-PCR and western blotting.
Confocal microscopy
For live microscopy, fibroblasts stably expressing SIRT4-EGFP were imaged
on a Leica SP5 confocal microscope using the 633 oil immersion objective.
For colocalization studies, SIRT4-EGFP stably expressing fibroblasts were
fixed and imaged on a Leica SP5 confocal microscope using the 633 glycerol
immersion objective, as described in the Extended Experimental Procedures.
Mitochondrial Isolation and Immunoaffinity Purification of
SIRT4-GFP
Purified mitochondria fractions were isolated from fibroblasts (25 3 106) by
removing nuclei using centrifugation, and further resolving the resulting crude
organelle pellet using a discontinuous OptiPrep gradient, as detailed in
Extended Experimental Procedures. SIRT4-EGFP and control EGFP were im-
munoaffinity purified from mitochondrial fractions using anti-GFP antibodiesCand M270 Epoxy Dynabeads, as described in [ (Cristea et al., 2005) and in
Extended Experimental Procedures.
Proteomic Analysis of SIRT4 and Interacting Protein Partners
SIRT4 immunoisolates were analyzed by mass spectrometry-based prote-
omics using an in-gel digestion approach followed by nanoliquid chromatog-
raphy (Dionex Ultimate3000) coupled directly to an LTQ-Orbitrap Velos
(ThermoFisher Scientific) mass spectrometer operated in data-dependent
acquisition mode, as described in Extended Experimental Procedures. The
specificity of candidate protein interactions was assessed using the SAINT al-
gorithm, as in (Choi et al., 2011) and in Extended Experimental Procedures.
The mass spectrometry proteomics data have been deposited to the Proteo-
meXchangeConsortium (Vizcaı´no et al., 2014) via the PRIDE partner repository
with the data set identifier PXD001447 and DOI 10.6019/PXD001447.
Western Immunoblotting
Proteins were transferred to nitrocellulose membranes, and protein and post-
translational modification levels were detected and visualized as described in
the Extended Experimental Procedures.
Recombinant Mitochondrial SIRT Proteins
N-terminally truncated human SIRT4 (33-314) was cloned, coexpressed with
GroEL and GroES in BL21(DE3) E. coli, and purified as described in Extended
Experimental Procedures. Recombinant SIRT3 and SIRT5 were purchased
from Sigma.
Peptide Synthesis and LC-MS-Based In Vitro Peptide Deacylation
Assays
Synthetic peptides were designed (Table 1), synthesized by GenScript, and
validated by infusion into an LTQ Orbitrap XL mass spectrometer (Thermo-
Fisher Scientific). The ability of SIRT4 to hydrolyze various acyl-lysine modifi-
cations was measured using LC-MS, as described in Extended Experimental
Procedures.
HPLC-Based SIRT Kinetic Assays
Kinetic assays for mitochondrial sirtuins and determination of kinetic parame-
ters were performed using HPLC-UV detection as described by others (Du
et al., 2011; Jiang et al., 2013) and in the Extended Experimental Procedures.
All analyses were performed in a minimum of three biological replicates.
Relative Quantification of Lipoyl-Lysine by Targeted Mass
Spectrometry
The relative abundance of lipoyl-lysine-containing DLAT peptides were
measured in mitochondria lysates using a selected reaction monitoring
(SRM/PRM) full-scan tandem mass spectrometry assay, as described in the
Extended Experimental Procedures.
PDH Activity Assay
The activity of the PDH was measured using the Pyruvate Dehydrogenase
Enzyme Activity Microplate Assay Kit (Abcam) according to manufacturer’s in-
structions, as detailed in Extended Experimental Procedures. All measure-
ments were performed in at least three biological replicates.
Animal Studies
Experiments in mice were conducted in compliance with Institutional Animal
Care and Use Committee (IACUC) of Princeton University. SIRT4 knockout
(Jackson Laboratory, Stock number 012756), and control (WT) (Jackson Lab-
oratory, Stock number 002448) adult female mice (n = 4) were euthanized,
livers excised, and mitochondria isolated as previously described (Rardin
et al., 2009) with modifications detailed in Extended Experimental Procedures.
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